Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Joseph J. Barchi is active.

Publication


Featured researches published by Joseph J. Barchi.


Tetrahedron Letters | 1993

Synthesis of cyclopropane-fused dideoxycarbocyclic nucleosides structurally related to neplanocin C

Juan B. Rodriguez; Victor E. Marquez; Marc C. Nicklaus; Joseph J. Barchi

Abstract The syntheses of five novel carbocyclic dideoxynucleosides with a bicyclo[3.1.0]hexane skeleton was accomplished via a Mitsunobu-type coupling reaction with various heterocyclic bases. These compounds appear to prefer a typical nucleoside northern conformation.


Journal of the American Chemical Society | 2012

Enhanced Epimerization of Glycosylated Amino Acids During Solid-Phase Peptide Synthesis

Yalong Zhang; Saddam Muthana; David Farnsworth; Olaf R. Ludek; Kristie M. Adams; Joseph J. Barchi; Jeffrey C. Gildersleeve

Glycopeptides are extremely useful for basic research and clinical applications, but access to structurally defined glycopeptides is limited by the difficulties in synthesizing this class of compounds. In this study, we demonstrate that many common peptide coupling conditions used to prepare O-linked glycopeptides result in substantial amounts of epimerization at the α position. In fact, epimerization resulted in up to 80% of the non-natural epimer, indicating that it can be the major product in some reactions. Through a series of mechanistic studies, we demonstrate that the enhanced epimerization relative to nonglycosylated amino acids is due to a combination of factors, including a faster rate of epimerization, an energetic preference for the unnatural epimer over the natural epimer, and a slower overall rate of peptide coupling. In addition, we demonstrate that use of 2,4,6-trimethylpyridine (TMP) as the base in peptide couplings produces glycopeptides with high efficiency and low epimerization. The information and improved reaction conditions will facilitate the preparation of glycopeptides as therapeutic compounds and vaccine antigens.


Nucleosides, Nucleotides & Nucleic Acids | 2005

ZEBULARINE: A UNIQUE MOLECULE FOR AN EPIGENETICALLY BASED STRATEGY IN CANCER CHEMOTHERAPY. THE MAGIC OF ITS CHEMISTRY AND BIOLOGY

Victor E. Marquez; Joseph J. Barchi; James A. Kelley; Kambhampati V. R. Rao; Riad Agbaria; Tsipi Ben-Kasus; Jonathan C. Cheng; Christine B. Yoo; Peter A. Jones

1-(β-D-ribofuranosyl)-1,2-dihydropyrimidin-2-one (zebularine) is structurally 4-deamino cytidine. The increased electrophilic character of this simple aglycon endows the molecule with unique chemical and biological properties, making zebularine a versatile starting material for the synthesis of complex nucleosides and an effective inhibitor of cytidine deaminase and DNA cytosine methyltransferase. Zebularine is a stable, antitumor agent that preferentially targets cancer cells and shows activity both in vitro and in experimental animals, even after oral administration.


ACS Chemical Biology | 2013

Sugar-Binding Proteins from Fish: Selection of High Affinity “Lambodies” That Recognize Biomedically Relevant Glycans

Xia Hong; Mark Z. Ma; Jeffrey C. Gildersleeve; Sudipa Chowdhury; Joseph J. Barchi; Roy A. Mariuzza; Michael B. Murphy; Li Mao; Zeev Pancer

Glycan-binding proteins are important for a wide variety of basic research and clinical applications, but proteins with high affinity and selectivity for carbohydrates are difficult to obtain. Here we describe a facile and cost-effective strategy to generate monoclonal lamprey antibodies, called lambodies, that target glycan determinants. We screened a library of yeast surface-displayed (YSD) lamprey variable lymphocyte receptors (VLR) for clones that can selectively bind various biomedically important glycotopes. These glycoconjugates included tumor-associated carbohydrate antigens (Tn and TFα), Lewis antigens (LeA and LeX), N-glycolylneuraminic acid, targets of broadly neutralizing HIV antibodies (poly-Man9 and the HIV gp120), and the glycoproteins asialo-ovine submaxillary mucin (aOSM) and asialo-human glycophorin A (aGPA). We isolated clones that bind each of these targets in a glycan-dependent manner and with very strong binding constants, for example, 6.2 nM for Man9 and 44.7 nM for gp120, determined by surface plasmon resonance (SPR). One particular lambody, VLRB.aGPA.23, was shown by glycan array analysis to be selective for the blood group H type 3 trisaccharide (BG-H3, Fucα1-2Galβ1-3GalNAcα), aGPA, and TFα (Galβ1-3GalNAcα), with affinity constants of 0.2, 1, and 8 nM, respectively. In human tissue microarrays this lambody selectively detected cancer-associated carbohydrate antigens in 14 different types of cancers. It stained 27% of non-small cell lung cancer (NSCLC) samples in a pattern that correlated with poor patient survival. Lambodies with exquisite affinity and selectivity for glycans may find myriad uses in glycobiology and biomedical research.


Journal of Medicinal Chemistry | 2008

Hydrolytic Reactivity Trends among Potential Prodrugs of the O2-Glycosylated Diazeniumdiolate Family. Targeting Nitric Oxide to Macrophages for Antileishmanial Activity

Joseph E. Saavedra; Brett M. Showalter; Keith M. Davies; Thomas C. Wilde; Michael L. Citro; Joseph J. Barchi; Jeffrey R. Deschamps; Damon A. Parrish; Stefan El-Gayar; Ulrike Schleicher; Christian Bogdan; Larry K. Keefer

Glycosylated diazeniumdiolates of structure R2NN(O)=NO−R′ (R′ = a saccharide residue) are potential prodrugs of the nitric oxide (NO)-releasing but acid-sensitive R2NN(O)=NO− ion. Moreover, cleaving the acid-stable glycosides under alkaline conditions provides a convenient protecting group strategy for diazeniumdiolate ions. Here, we report comparative hydrolysis rate data for five representative glycosylated diazeniumdiolates at pH 14, 7.4, and 3.8−4.6 as background for further developing both the protecting group application and the ability to target NO pharmacologically to macrophages harboring intracellular pathogens. Confirming the potential in the latter application, adding R2NN(O)=NO−GlcNAc (where R2N = diethylamino or pyrrolidin-l-yl and GlcNAc = N-acetylglucosamin-l-yl) to cultures of infected mouse macrophages that were deficient in inducible NO synthase caused rapid death of the intracellular protozoan parasite Leishmania major with no host cell toxicity.


FEBS Letters | 1996

Structural comparison of a 15 residue peptide from the V3 loop of HIV-1IIIb and an O-glycosylated analogue

Xiaolin Huang; M. Charles Smith; Jay A. Berzofsky; Joseph J. Barchi

As part of a program to study the effect of glycosylation on the three‐dimensional structures of HIV‐1 IIIB V3 peptide constructs, we have examined the solution structures of a 15 residue peptide (RIQRGPGRAFVTIGK, P18 IIIB ), originally mapped as an epitope recognized by CD8+ D d class I MHC‐restricted murine cytotoxic T‐lymphocytes (CTL), and an analogue (P18 IIIB ‐g), O‐glycosylated with an α‐galactosamine on Thr‐12, using NMR, circular dichroism and molecular modeling methods. Our studies show that the peptides sample mainly random conformations in aqueous solution near 25°C and become more ordered by the addition of trifluoroethanol. Upon decreasing the temperature to 5°C, a reverse turn is formed around the immunodominant tip (G5−R8). Glycosylation on T12 ‘tightens’ the turn slightly as suggested by NOE and CD analysis. In addition, the sugar has a defined conformation with respect to the peptide backbone and influences the local peptide conformation. These data suggest that simple glycosylation may influence the conformational equilibrium of a V3 peptide which contains a domain critical for antibody recognition and virus neutralization. We also show that the ability of cytotoxic T‐lymphocytes (CTL) to lyse tumor cells presenting P18 IIIB was completely abrogated by threonine glycosylation.


Journal of Biological Chemistry | 2013

Recognition of the Thomsen-Friedenreich Pancarcinoma Carbohydrate Antigen by a Lamprey Variable Lymphocyte Receptor

Ming Luo; Velikovsky Ca; Xiuli Yang; Siddiqui Ma; Xia Hong; Joseph J. Barchi; Gildersleeve Jc; Zeev Pancer; Roy A. Mariuzza

Background: Variable lymphocyte receptors (VLRs) bind tumor-associated carbohydrates, such as Thomsen-Friedenreich antigen (TFα), with high selectivity. Results: The crystal structure of a VLR-TFα complex coupled with thermodynamic analysis revealed the basis for selectivity. Conclusion: VLRs utilize leucine-rich repeats to recognize glycans with affinity comparable to that of lectins and antibodies. Significance: The VLR-TFα structure provides a template for engineering VLRs to bind biomedically relevant glycans. Variable lymphocyte receptors (VLRs) are leucine-rich repeat proteins that mediate adaptive immunity in jawless vertebrates. VLRs were recently shown to recognize glycans, such as the tumor-associated Thomsen-Friedenreich antigen (TFα; Galβ1–3GalNAcα), with a selectivity rivaling or exceeding that of lectins and antibodies. To understand the basis for TFα recognition by one such VLR (VLRB.aGPA.23), we measured thermodynamic parameters for the binding interaction and determined the structure of the VLRB.aGPA.23-TFα complex to 2.2 Å resolution. In the structure, four tryptophan residues form a tight hydrophobic cage encasing the TFα disaccharide that completely excludes buried water molecules. This cage together with hydrogen bonding of sugar hydroxyls to polar side chains explains the exquisite selectivity of VLRB.aGPA.23. The topology of the glycan-binding site of VLRB.aGPA.23 differs markedly from those of lectins or antibodies, which typically consist of long, convex grooves for accommodating the oligosaccharide. Instead, the TFα disaccharide is sandwiched between a variable loop and the concave surface of the VLR formed by the β-strands of the leucine-rich repeat modules. Longer oligosaccharides are predicted to extend perpendicularly across the β-strands, requiring them to bend to match the concavity of the VLR solenoid.


Tetrahedron Letters | 1994

A diastereoselective synthesis of (S,S)-α-fluoro-2,2-dimethyl-1,3-dioxolane-4-propanoic acid methyl ester, a key intermediate for the preparation of anti-HIV effective fluorodideoxynucleosides

Maqbool A. Siddiqui; Victor E. Marquez; John S. Driscoll; Joseph J. Barchi

(S,S)-α-fluoro-2,2-dimethyl-1,3-dioxolane-4-propanoic acid methyl ester (10), a key intermediate for the preparation of anti-HIV active 9-(2,3-dideoxy-2-fluoro-β-D-threo-pentofuranosyl)adenine (1, FddA) and 1-(2,3-dideoxy-2-fluoro-β-D-threo-pentofuranosyl)cytosine (2, FddC) was prepared via the diastereoselective fluorination of the chiral imide enolate obtained from 8 with N-fluorobenzenesulfonimide. The overall yield of 10 from the readily available 1,2:5,6-di-O-isopropylidene-D-mannitol was 25% (de 93%).


Chemical Biology & Drug Design | 2011

Normalization of Proliferation and Tight Junction Formation in Bladder Epithelial Cells from Patients with Interstitial Cystitis/Painful Bladder Syndrome by d‐Proline and d‐Pipecolic Acid Derivatives of Antiproliferative Factor

Susan Keay; Piotr Kaczmarek; Chen-Ou Zhang; Kristopher R. Koch; Zoltan Szekely; Joseph J. Barchi; Christopher J. Michejda

Interstitial cystitis/painful bladder syndrome is a chronic bladder disorder with epithelial thinning or ulceration, pain, urinary frequency and urgency, for which there is no reliably effective therapy. We previously reported that interstitial cystitis/painful bladder syndrome bladder epithelial cells make a glycopeptide antiproliferative factor or ‘APF’ (Neu5Acα2‐3Galβ1‐3GalNAcα‐O‐TVPAAVVVA) that induces abnormalities in normal cells similar to those in interstitial cystitis/painful bladder syndrome cells in vitro, including decreased proliferation, decreased tight junction formation, and increased paracellular permeability. We screened inactive APF derivatives for their ability to block antiproliferative activity of asialylated‐APF (‘as‐APF’) in normal bladder cells and determined the ability of as‐APF‐blocking derivatives to normalize tight junction protein expression, paracellular permeability, and/or proliferation of interstitial cystitis/painful bladder syndrome cells. Only two of these derivatives [Galβ1‐3GalNAcα‐O‐TV‐(d‐pipecolic acid)‐AAVVVA and Galβ1‐3GalNAcα‐O‐TV‐(d‐proline)‐AAVVVA] blocked as‐APF antiproliferative activity in normal cells (p < 0.001 for both). Both of these antagonists also 1) significantly increased mRNA expression of ZO‐1, occludin, and claudins 1, 4, 8, and 12 in interstitial cystitis/painful bladder syndrome cells by qRT‐PCR; 2) normalized interstitial cystitis/painful bladder syndrome epithelial cell tight junction protein expression and tight junction formation by confocal immunofluorescence microscopy; and 3) decreased paracellular permeability of 14C‐mannitol and 3H‐inulin between confluent interstitial cystitis/painful bladder syndrome epithelial cells on Transwell plates, suggesting that these potent APF antagonists may be useful for the development as interstitial cystitis/painful bladder syndrome therapies.


Journal of Medicinal Chemistry | 2008

Structure-activity relationship studies for the peptide portion of the bladder epithelial cell antiproliferative factor from interstitial cystitis patients.

Piotr Kaczmarek; Susan Keay; Gillian M. Tocci; Kristopher R. Koch; Chen-Ou Zhang; Joseph J. Barchi; David Grkovic; Li Guo; Christopher J. Michejda

We performed comprehensive structure-activity relationship (SAR) studies on the peptide portion of antiproliferative factor (APF), a sialylated frizzled-8 related glycopeptide that inhibits normal bladder epithelial and urothelial carcinoma cell proliferation. Glycopeptide derivatives were synthesized by solid-phase methods using standard Fmoc chemistry and purified by RP-HPLC; all intermediate and final products were verified by HPLC-MS and NMR analyses. Antiproliferative activity of each derivative was determined by inhibition of (3)H-thymidine incorporation in primary normal human bladder epithelial cells. Structural components of the peptide segment of APF that proved to be important for biological activity included the presence of at least eight of the nine N-terminal amino acids, a negative charge in the C-terminal amino acid, a free amino group at the N-terminus, maintenance of a specific amino acid sequence in the C-terminal tail, and trans conformation for the peptide bonds. These data provide critical guidelines for optimization of structure in design of APF analogues as potential therapeutic agents.

Collaboration


Dive into the Joseph J. Barchi's collaboration.

Top Co-Authors

Avatar

Victor E. Marquez

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Maqbool A. Siddiqui

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Marc C. Nicklaus

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

James A. Kelley

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

John S. Driscoll

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Chen-Ou Zhang

University of Maryland Medical Center

View shared research outputs
Top Co-Authors

Avatar

Harry Ford

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Susan Keay

University of Maryland

View shared research outputs
Top Co-Authors

Avatar

Terrence R. Burke

National Institutes of Health

View shared research outputs
Researchain Logo
Decentralizing Knowledge